This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets.
Changes to authorisations most relevant to vets
The changes to authorisations most relevant to vets can be found below. Each product listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics sections have been revised/changed. All entries can be found on the VMD’s Product Information Database here. Changes to the SPC, labels and leaflets may change how the medicines should be used. There may be a delay between these changes being authorised to implementation on product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.
The changes to authorisations most relevant to vets can be found below. Each product listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics sections have been revised/changed.
All entries can be found on the VMD’s Product Information Database.
Changes to the SPC, labels and leaflets may change how the medicines should be used. There may be a delay between these changes being authorised to implementation on product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.
Buscopan Compositum Solution for injection
Boehringer Ingelheim Animal Health UK Ltd UK POM-V Cattle, Dogs, Horses
Section 4.5: Due to the risk of anaphylactic shock metamizole-containing solutions should be administered slowly when given intravenously.
Section 4.6: In horses, a slight transient increase in heart rate may be observed due to the parasympatholytic activity of butylscopolaminiumbromide (hyoscine butylbromide). In very rare cases, cardiovascular shock may occur if the intravenous injection is administered too fast.
In horses, mild tachycardia may be observed occasionally due to the parasympatholytic activity of hyoscine butylbromide.
In very rare cases, anaphylactic reactions may occur and should be treated symptomatically.
Section 4.8: Concomitant use of inducers of hepatic microsomal enzymes (e.g., barbiturates, phenylbutazone) reduces the half-life period and hence the duration of action of metamizole. Simultaneous administration of neuroleptics, especially phenothiazine derivatives, may lead to severe hypothermia. Furthermore, the risk of gastro-intestinal bleeding is increased upon concurrent use of glucocorticoids. The diuretic effect of furosemide is attenuated. Co-administration of other weak analgesics increases the effects and side effects of metamizole. The anticholinergic action of quinidine and antihistaminic as well as the tachycardic effects of β sympathomimetics may be enhanced by this veterinary medicinal product.
Ophtocycline 10 mg/g Eye ointment for dogs, cats and horses
Le Vet Beheer B.V. UK POM-V
Section4.6: Application site reactions and eye disorders like irritation, pruritus, oedema and reddening have been very rarely reported after administration of Ophtocycline in isolated cases in spontaneous reports.
For more information, contact the VMD at postmaster@vmd.gov.uk